Oncotarget

Clinical Research Papers:

IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma

Qiulu Zhong, Xiaodong Zhu _, Ling Li, Song Qu, Zhongguo Liang, Fanyan Zeng and Xinbin Pan

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:39683-39694. https://doi.org/10.18632/oncotarget.14799

Metrics: PDF 1164 views  |   HTML 1192 views  |   ?  


Abstract

Qiulu Zhong1, Xiaodong Zhu1, Ling Li1, Song Qu1, Zhongguo Liang1, Fanyan Zeng1 and Xinbin Pan1

1 Department of Radiation Oncology, The Affiliated Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China

Correspondence to:

Xiaodong Zhu, email:

Keywords: nasopharyngeal carcinoma; intensity-modulated radiotherapy; concurrent chemoradiotherapy; concurrent chemoradiotherapy plus adjuvant chemotherapy

Received: August 15, 2016 Accepted: December 07, 2016 Published: January 23, 2017

Abstract

Purpose: To evaluate the efficacy of IMRT combined with concurrent chemotherapy followed by adjuvant chemotherapy compared with IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.

Methods: From January 2007 to December 2014, we collected 797 staged II-IVb [UICC = Union for International Cancer Control criteria (7th edition)] NPC patients for analysis. After 1:1 matching ,we selected 261 cases as the CCRT group, another 261 patients as the CCRT+AC group. Using Kaplan-Meier to calculate the overall survival (OS), locoregional failure-free survival(LFFS), distant metastasis failure-free survival(DMFS). The log-rank test and Cox-proportional hazards model to evaluate the prognostic factors.

Results: After matching, there were 261 patients in each group. In CCRT+AC group, The 1-,2- and 3- year os rates were a little higher than in CCRT group(99.6% vs 97.9%,97.4% vs 96.2%,93.8% vs 86.9%, P = 0.150). There were no significant difference in 1-,2-,3- year OS, LFFS, DMFS between the two groups. In subgroup analysis, a little higher OS rate in CCRT+AC group for staged III, IV and T4(III:100% vs 100%, 97.6% vs 95.8%, 94.0% vs 84.0%; IV: 99.1% vs 95.4%, 96.3% vs 95.4%, 90.5% vs 79.4%, P = 0.047;T4:99.1% vs 95.2%, 97.1% vs 95.2%, 90.9% vs 78.2%, P = 0.055). No significant difference were observed in OS, LFFS,DMFS between the groups.

Conclusion: IMRT combined with concurrent chemotherapy followed by adjuvant chemotherapy might improved 1-,2-,3- year of OS. Whether or not add adjuvant chemotherapy it had similar LFFS rate and DMFS rate in patients with nasopharyngeal carcinoma. Locally advanced NPC patients (III, IV and T4)might benefit from the adjuvant chemotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14799